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In their recent article “Lorazepam-Assisted Interview in a Resistant Case of Functional 
Dysphonia”, Modak et al. (2019) describe the use of Lorazepam in drug-assisted 
interviews for the treatment of a resistant case of functional dysphonia. 
 
Although we are pleased to see further research into the treatment of resistant functional 
dysphonia, we have serious concerns regarding the diagnosis of functional dysphonia in 
the case presented. The article describes a 40-year-old gentleman with sudden onset of 
articulation difficulties, being “unable to make movements of the tongue while speaking 
although power and range of movement were normal”.  The authors report that the 
gentleman was “able to produce sounds but had lost the ability to modulate sounds into 
meaningful words”.  
 
In viewing the excellent supplemental case videos accompanying the article, the 
symptoms evident were limited movement of the articulators with a relatively fixed open 
jaw position, abnormal fixed tongue positioning with the tongue held anteriorly and on 
the floor of the mouth throughout speech production, slow rate and monotonous speech 
quality with equal and excess stress on words.  Post treatment, normal tongue, lip and 
jaw movement is observed, with the speech remaining monotonous with equal and 
excess stress. Normal phonation is present throughout the pre-treatment and post-
treatment video recordings suggesting no disruption to vocal fold movement or vocal 
function.   
 
While differential diagnosis of organic versus functional neurological disorder was 
discussed by the authors, we would respectfully suggest that this case required careful 
attention to the differential diagnosis between a functional/psychogenic dysphonia (see 
Baker, 2016) over functional/psychogenic speech disorder (see Duffy, 2016). Clearly the 
symptoms we observed from the videos as well as those described by the authors in the 
article, were of marked alterations to articulation rather than phonation. The article 
therefore describes the treatment of a functional/psychogenic speech disorder and as 
such, the title of the article is misleading. 
 
We feel that the article by Modak et al. 2019 highlights the need for clear criteria that 
enables differential diagnosis of functional-psychogenic dysphonia and the need for 
authors to include transparent inclusion and exclusion criteria based on these criteria in 
future studies on functional voice disorders. 
 
Baker, J. (2016) ‘Functional voice disorders: clinical presentations and differential diagnosis’, in Hallett, M., 
Stone, J., and Carson, A. (eds) Functional Neurologic Disorders, Volume 139 of the Handbook of Clinical Neurology 
series. Elsevier, pp. 389–406. 
Duffy, J. R. (2016) ‘Functional speech disorders: clinical manifestations, diagnosis, and management’, in Hallett, 
M., Stone, J., and Carson, A. (eds) Functional Neurologic Disorders, Volume 139 of the Handbook of Clinical 
Neurology series. Elsevier, pp. 379–388.   
